Recurrent potentially inactivating SVs in SFMBT2 included the following: (1) an ETV6::RUNX1+ case (ALL10) with translocation t(2;10)(q37.1;p14), leading to fusion of the promotor region to DGKD and a concomitant loss of the whole SFMBT2 gene; (2) an ETV6::RUNX1+ case (ALL5) with a translocation t(10;19)(p14;p13.3) that might lead to disruption of SFMBT2 and UHRF1; and (3) a HD case with an intragenic focal deletion (45 kb; chr10:7,286,100–7,343,440 bp), which hints at a potential role in leukemogenesis. This evidence concerns the gene SFMBT2 and Huntington disease.